Brazil Diabetes Market Size, Share and Future Outlook 2026–2034

Brazil diabetes market grew from USD 2.15 Billion in 2025 to USD 2.27 Billion in 2026. Looking forward, the market is expected to reach USD 3.09 Billion by 2034, exhibiting a CAGR of 3.96% during 2026-2034.

Nov 20, 2026 - 14:53
Nov 20, 2026 - 14:54
 0  92
Brazil Diabetes Market Size, Share and Future Outlook 2026–2034
Brazil Diabetes Market Size, Share and Future Outlook 2026–2034

Brazil Diabetes Market Report 2026

Market Size in 2025: USD 2.15 Billion

Market Size in 2026: USD 2.27 Billion

Market Forecast in 2034: USD 3.09 Billion

Market Growth Rate: 3.96% (2026-2034)

According to a recent study by IMARC Group Research Report, titled “Brazil Diabetes Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2026-2034,” the Brazil diabetes market grew from USD 2.15 Billion in 2025 to USD 2.27 Billion in 2026. Looking forward, the market is expected to reach USD 3.09 Billion by 2034, exhibiting a CAGR of 3.96% during 2026-2034.

Brazil Diabetes Industry Trends and Demands in 2026:

Brazil’s diabetes market is undergoing transformative change in 2026, driven by rapidly rising urbanization, sedentary lifestyles, and the resulting escalation in type 2 diabetes prevalence across all demographic segments. The GLP-1 receptor agonist segment is experiencing unprecedented growth, with the injectable semaglutide market generating over BRL 6.5 billion in the 12 months to July 2025 — representing a 58% year-on-year increase — as Brazilian cardiologists and endocrinologists accelerate prescribing of SGLT-2 inhibitors and GLP-1 agonists. The expiry of Novo Nordisk’s semaglutide patent in Brazil in March 2026 has triggered a new era of market competition, with local manufacturers and international generics players entering the segment and driving prices down significantly.

E-commerce and tele-pharmacy distribution channels are expanding patient reach across Brazil’s underserved North and Northeast regions, improving treatment accessibility for previously disconnected diabetes patient populations. Brazil’s ANVISA approved 14 new injectable pens for diabetes and obesity treatment in 2026 following the semaglutide patent expiry, dramatically broadening the competitive landscape. Key players including Novo Nordisk, Sanofi, Lilly, AstraZeneca, and domestic manufacturers such as EMS and Eurofarma are investing heavily in product localization, biosimilar insulin development, and portfolio expansion strategies to capitalize on Brazil’s rapidly evolving and highly competitive diabetes treatment market.

How AI is Reshaping the Future of the Brazil Diabetes Market:

  • AI-Powered Continuous Glucose Monitoring and Predictive Glycemic Management: Artificial intelligence is revolutionizing diabetes management in Brazil by enabling continuous glucose monitoring systems to deliver predictive glycemic insights rather than merely reactive readings. AI algorithms analyze blood glucose trends, meal patterns, physical activity, and medication timing to anticipate hypoglycemic or hyperglycemic episodes before they occur, enabling proactive intervention. This capability is significantly improving glycemic control outcomes for Brazilian diabetes patients and is being rapidly integrated into connected health ecosystems spanning hospitals, pharmacies, and tele-health platforms across the country.

  • AI-Driven Drug Discovery and Biosimilar Development: AI-powered drug discovery platforms are accelerating the development of next-generation diabetes therapies and biosimilar insulin formulations for Brazil’s rapidly evolving pharmaceutical market. Machine learning models analyze molecular interaction data, clinical trial results, and patient response patterns to identify promising drug candidates and optimize biosimilar formulation processes. As Brazil’s semaglutide patent landscape opens competitive space, domestic manufacturers, including EMS, are leveraging AI-assisted development processes to accelerate time-to-market for affordable GLP-1 alternatives targeting Brazil’s large and growing diabetes patient population. These advancements are also supporting innovation and competition in the Brazil diabetes drugs market, expanding the potential availability of more accessible and effective treatment options.

  • AI-Enabled Patient Adherence and Digital Therapeutics: AI digital health platforms are addressing Brazil’s significant diabetes medication adherence challenge by delivering personalized reminders, lifestyle coaching, and behavioral interventions through smartphone applications. Machine learning systems analyze patient behavior patterns, medication histories, and self-reported data to identify non-adherence risks and trigger targeted support interventions through tele-pharmacy platforms and digital health programs. This capability is expanding treatment effectiveness across Brazil’s vast geographic territory, particularly in reaching patients in underserved regional markets where specialist care access remains limited.

Brazil Diabetes Market Segmentation:

The market report offers a comprehensive analysis of the segments, highlighting those with the largest Brazil diabetes market share. It includes forecasts for the period 2026-2034 and historical data from 2020-2025 for the following segments.

Breakup by Segment:

  • Oral Antidiabetics

  • Insulin

Breakup by Distribution Channel:

  • E-commerce and Tele-pharmacy

  • Hospital Pharmacies

  • Retail Pharmacies

Regional Insights:

  • Southeast

  • South

  • Northeast

  • North

  • Central-West

Competitive Landscape:

The report offers an in-depth examination of the competitive landscape. It includes a thorough competitive analysis encompassing market structure, key player positioning, leading strategies for success, a competitive dashboard, and a company evaluation quadrant. Additionally, the report features detailed profiles of all major companies in the Brazil Diabetes industry.

  • Novo Nordisk A/S

  • Sanofi

  • Lilly USA, LLC

  • AstraZeneca

  • Merck & Co. Inc.

Recent News and Developments in Brazil Diabetes Market:

May 2026: Brazil’s ANVISA approved Ozivy — EMS’s biosimilar semaglutide injectable pen — marking the country’s first generic copy of Novo Nordisk’s Ozempic following the March 2026 patent expiry. EMS planned to launch the product at approximately 30% lower than Ozempic’s price, with initial production capacity of 350,000 pre-filled pens, signaling a major competitive shift in Brazil’s GLP-1 diabetes and obesity treatment market.

March 2026: Brazilian drugmaker EMS acquired Sanofi’s Brazil-based generic manufacturer Medley for over USD 500 million, with the combined entity projected to control approximately 30% of Brazil’s generics market pending CADE regulatory approval. EMS also announced plans to launch its own semaglutide-based injector pens to compete directly in Brazil’s rapidly expanding diabetes and obesity treatment segment.

Ongoing: Eurofarma, in partnership with Novo Nordisk, launched Poviztra and Extensior — injectable semaglutide products for obesity and type 2 diabetes — in Brazil, while Novo Nordisk re-submitted Wegovy to Brazil’s CONITEC with a 59% price discount for potential SUS inclusion. The resulting multi-brand competition is driving price reductions and significantly expanding patient access to innovative GLP-1 therapies throughout Brazil’s healthcare system.

Note: If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
\